Biotech Showcase Event 2015 Investment into T-Cell Therapy Accelerates
Promising growth and recent breakthroughs have accelerated investment into the T-cell therapy industry targeting many types of cancer. New capital investment continues to fund innovative biotech firms with steady clinical trial progress and positive outcomes for many cancer patients.
San Francisco, California, February 6, 2015 (Newswire.com) - The 7th Annual Investor and Partnering Conference, Biotech Showcase 2015, held in San Francisco, was truly a success. The three day event is co-produced by EBD Group and Demy-Colton Life Science Advisors. The Biotech Showcase is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and life science investment.
Some highlights from the event more than 300 individual investors attended this year’s seventh annual Biotech Showcase. Over 2,100 executive-level delegates representing qualified private and public equity investors. Industry analysts, bankers, pharmaceutical and biotechnology executives attended from 1,287 companies and participated in nearly 4,300 one-to-one partnering meetings. There were 232 presentations from public and private biotech companies.
The forum offers excellent opportunities to showcase activities and highlight investment opportunities. In addition to the presenting companies, Biotech Showcase features a top-notch panel of biotech plenary sessions. The business workshop included “The Tactics of Closing Funding Deals” presented by Phil Haworth and Jack Anthony from BioMentorz a firm based in South San Francisco.
Presenters included James Nobel, CEO, of Adaptimmune Limited a clinical-stage cell therapy company targeting cancer. The British biotech company was established in 2008, with offices in Oxford UK and in Philadelphia. Adaptimmune is focused on the use of T-cell therapy to treat cancer and infectious disease. The body’s own machinery is used to target and destroy cancerous or infected cells by using engineered, increased affinity T-cell receptor (TCRs) as a means of strengthening natural patient T-cell responses and overcoming tolerance to cancer.
Adaptimmune has multiple clinical trials underway for engineered TCR T-cell therapy in the United States. The company has raised $104 million in September of 2014 and is corporate partners with GSK. The therapeutic focus and outlook is promising for T-cell therapy for patients suffering from multiple types of cancer.
Next year’s event Biotech Showcase 2016 Investor and Partnering Conference will be held January 11–13, 2016 in San Francisco, CA at Parc 55 Wyndham Hotel, located in Union Square.